Reaktionsgleichung
CC(CCC[C@H:7]([C@@H:9]1[C@:27]2(C)[C@H:12]([C@H:13]3[C@H:24]([CH2:25][CH2:26]2)[C@:22]2(C)[C:16](C[C@H:18]([CH2:20][CH2:21]2)[OH:19])=[CH:15][CH2:14]3)[CH2:11][CH2:10]1)[CH3:8])C.C1C(NCCN)=C2C(C3C=CN=CC=3C(=O)C2=C(NCCN)C=1)=[O:40]>>[CH3:8][CH2:7][CH2:9][CH2:10][CH2:11]/[CH:12]=[CH:27]\[CH2:26]/[CH:25]=[CH:24]\[CH2:13][CH2:14][CH2:15][CH2:16][CH2:22][CH2:21][CH2:20][C:18]([OH:19])=[O:40]Komponenten
Versuchsvorschrift
Therefore, the invention provides a liposome formulation of compound BBR 2778 consisting of liposomes comprising phosphatidylcholine, cholesterol and BBR 2778, in a cholesterol/phospholipide 1:2 to 1:7 weight ratio and in a BBR 2778/phospholipide 1:4 to 1:25 weight ratio. Phosphatidylcholine preferably includes residues of fatty acids selected from palmitic, oleic, linoleic, gamma-linoleic, linolenic and stearic acids, and the liposome is formed by a mixture of hydrogenated and non-hydrogenated phosphatidylcholines, having the fatty acids composition indicated, in a 1:2 to 2:1 ratio, more preferably said mixture consists of hydrogenated phosphatidylcholine having melting point of 120° C. and crystallization point of 90° C., and non-hydrogenated phosphatidylcholine having a thermogram as reported in FIG. 5. The hydrogenated and non-hydrogenated phosphatidylcholines, having the above-indicated composition, are commercially available respectively under the name PHOSPHOLIPON® 90 H and PHOSPHOLIPON® 90.
Quellen und Nachweise
- ORD-Eintrag
- ord-c770887302674161a3326f12bf9f0eb7
- Quelldatensatz
- uspto-grants-2008_11
- Patentnummer
- US07449197B2
Verknüpfte Notizen
Wird geladen…